Background. Human cytomegalovirus (HCMV) is a leading cause of virally induced congenital disorders and morbidities in immunocompromised individuals, ie, transplant, cancer, or acquired immune deficiency syndrome patients. Human cytomegalovirus infects virtually all cell types through the envelope glycoprotein complex gH/gL/gO with or without a contribution of the pentameric gH/gL/pUL128L. Together with gH/gL, the HCMV envelope glycoprotein B (gB) contributes to the viral fusion machinery.
Monocytes were isolated by immunomagnetic separation (Miltenyi Biotec, Bergisch Gladbach, Germany) or by elutriation (DTC, Nantes University Hospital/Biogen Ouest, Nantes, France) from healthy donors (>95% purity). Monocytes were differentiated into MDDC as previously described [23] with 20 ng/mL recombinant human interleukin-4 (CellGenix, Freiburg, Germany), 100 ng/mL granulocyte-macrophage colony-stimulating factor (Gentaur, Paris, France), and 2% human serum albumin (Vialebex, LFB, Coutaboeuf, France). U937, HEK293T cells (American Type Culture Collection number CRL-3216; LGC Standards, Teddington, UK), and MRC-5 (RD Biotech, Besançon, France) were propagated as described elsewhere [14] .
Viruses and Reagents
TRI, an in-house clinical isolate (no sequence data available yet), 3 low passage HCMV laboratory strains (Toledo, TB40/E-GFP and VHL/E; a gift from Dr. Christian Sinzger) [24, 25] , and BAC4-based HCMV gB-mutated viruses were propagated on MRC-5 cells and used as clarified viral supernatants for trans-infection experiments at a multiplicity of infection (MOI) ranging from 2 to 10. Cytomegalovirus (CMV) supernatants were also tittered by quantitative polymerase chain reaction (qPCR) as described elsewhere [26] . Chinese hamster ovary (CHO)-derived recombinant HCMV gB and human immunodeficiency virus (HIV)-1 IIIB gp120 were purchased from Sanofi Pasteur (Marcy l'Etoile, France) and ImmunoDx (Woburn, MA), respectively. Glycoproteins were used either as purified or fluorescence-conjugated reagents (Molecular Probes, Thermo Fisher Scientific, Waltham, MA). Antibodies against AD-4/5 (clones SM5-1 and 1G2) and AD-1/2 (clones ITC33, ITC39, ITC48, ITC52, ITC63, and ITC88) [27] were kindly provided by Professor Michael Mach and Dr. Mats Ohlin, respectively. A polyclonal antibody (pAb) against gB was purchased from Sino Biological ([10202-RP01-100], Beijing, China). Fifteen antihuman DC-SIGN antibodies from Dendritics SA (Lyon, France) were used in this study. Four clones, 103G2.07, 111E3.04, 102E11.06, and 111H2.02, are directed against the neck region (amino acide [AA] 96-257), whereas 9 (clones 104B4.01, 103F12.01, 109H12.03, 113B11.02, 106A4.01, 120E12.03, 108H8.05, 105E9.01, and 114F1.08) were targeting the CRD (AA, 258-404). We considered that clone 108C7.01 recognized both the extracellular proximal region ([ECPR] AA 59-95) and the CRD, whereas clone 102F10.04 bound to the ECPR alone (see Supplementary Table 2) . Four other commercially available anti-DC-SIGN monoclonal antibodies (mAb), clones MR1 (Bio-Rad AbDSerotec, Oxford, UK), AZN-D1 (Beckman Coulter France, Villepinte, France), 1B10, and an anti-neck (H200, Santa Cruz Biotechnology Inc., Heidelberg, Germany), were also used here. Antibodies targeting platelet-derived growth factor receptor (PDGFR)α (aR1), the β 1 chain integrin (MAR4), and the α V β 3 integrin (23C6) were purchased from BD Biosciences (Franklin Lakes, NJ). Antibodies were used at 20 µg/mL for blockade experiments.
Viral Envelope Glycoprotein Binding Assay
Cells were resuspended in a binding buffer (Tris-buffered saline, 1 mM CaCl 2 , 2 mM MgCl 2 ; 0.1% bovine serum albumin) and seeded in 96-well plates at 1 × 10 5 cells/wells. Dendritic cell-SIGN/gB interaction blockade was performed by incubating cells with antibodies for 30 minutes at 4°C. Conjugated gB or HIV-1 IIIB gp120 (2 µg/mL) were added to cells for 20 minutes at 4°C without washing. After 3 washes with ice-cold binding buffer, cells were analyzed on a LSR II flow cytometer (BD Biosciences, Franklin Lakes, NJ) with FlowJo (Tree Star, Ashland, OR). Surface plasmon resonance was carried out with soluble gB and recombinant DC-SIGN extracellular domain [28] .
Transinfection Experiments
Cells were incubated with blockers for 30 minutes at 4°C if necessary before adding virus (MOI = 2) without washing. After a subsequent 2-hour incubation at 37°C, cells were washed and cultured with 70%-80% confluent MRC-5 cells for 48-72 hours. Cells were fixed in acetone/water 9:1 (volume/volume) and further stained with an Alexa Fluor 488-conjugated anti-IE/E antigen antibody (8B1.2; Millipore, Burlington, MA). Percentages of IE/E+ cells were determined on 4 fields per condition with Fiji (SciJava consortium; http://scijava.org/).
Statistical Analysis
Statistical tests were performed using the Graph Pad Prism 5.0 software (Graph Pad Software Inc., La Jolla, CA). On-way analysis of variance was applied to all data of this manuscript. P values below or equal to .05 were considered significant. Additional materials and methods are available in Supplementary Materials. [14] . To that purpose, HEK293T cells were modified to express wild-type (WT) DC-SIGN (AA 1-404; UnitProtKB, Q9NNX6) or 2 deletion mutants, respectively, lacking neck repeats (AA 1-80 in frame with AA 253-404, called Δneck) or the CRD (AA 1-252, called ΔCRD) in fusion with the enhanced green fluorescent protein (eGFP) [29] . All cells expressed comparable eGFP levels and DC-SIGN cell surface expression as well ( Figure 1A ). We showed that gB interacts with CRD-containing DC-SIGN molecules and does not require the neck repeats ( Figure 1A and B) .
Then, we sought to identify CRD AA involved in this interaction. We hypothesized that AA taking part to the calcium ion coordination or sugar binding could be detrimental [20, 30] . Single-point mutants were generated and further expressed in HEK293T cells. Antineck staining showed similar DC-SIGN expression across all cell lines (Supplementary Figure 1) . Their ability to bind gB was then assessed by flow cytometry ( Figure 1C ). E347, N349, E354, N365, and D366 form the calcium binding "site 2" and enable contact with high-mannose sugars as well [30, 31] . Expectedly, mutations at these positions precluded interaction with gB ( Figure 1D ). Similarly, mutants D320A, E324A, N350A, and D355A lost their ability to optimally bind gB, assuming that it was likely due to substantial fold changes in the calcium binding "site 1" as proposed for HIV-1 gp120 [32] . Here, F313Y, Q323E, and K368A DC-SIGN mutations were ineffective ( Figure 1D ). Moreover, we confirmed that the E354Q within site 2 broke the interaction [33] . The V351 residue was shown to discriminate between endogenous and pathogen-derived ligands such as ICAM-3 and HIV-1 gp120 or hepatitis C virus E1/E2, respectively [32, 34, 35] . In this study, we analyzed 2 mutations, ie, V351G and V351T. The V351G mutant lost its binding capacity to gB, suggesting that this AA is as important as its human herpesvirus (HHV)-8 counterpart and ICAM-3 [36] . It is interesting to note that a methyl group substitution of the V351 by a hydroxyl group of a threonine conserved a nominal binding activity, suggesting that subtle variations in the DC-SIGN fold could determine its ability to recognize unrelated ligands. Taken together, these results demonstrate that gB utilizes the same CRD AA as the HHV-8 gB or even ICAM-3.
Recombinant Glycoprotein B Contains High-Mannose Sugars
Glycoprotein B and HIV-1 gp120 are both able to bind to DC-SIGN, although their respective folds are distinct. We postulated that their glycan covers might be similar. Prototypical Nor O-glycans are depicted in the Figure 2A . Culture wells were coated with various lectins from plant or mammalian origins to characterize glycans on CHO-derived gB. Human immunodeficiency virus-1 gp120 was used as a control of a high mannose-containing glycoprotein. In line with other pioneering studies on gp120 [20] , we observed dose-dependent binding of both glycoproteins to DC-SIGN, concanavalin A, and, to a lesser extent, to wheat germ agglutinin (WGA), suggesting that high mannose-containing N-glycans were decorating gB and gp120 ( Figures 2B and C) . Binding to Datura stramonium Agglutinin, and also to a lesser extent to WGA (due to its double specificity), confirmed the presence of N-acetylglucosamine. A weak binding to Maclura pomifera agglutinin (MPA) at the highest gB concentration suggested that O-glycans were almost absent. No significant signal was observed with Sambucus nigra agglutinin.
Next, we used whole HCMV virions to perform the same kind of experiments. Here, virus attachment to lectins was quantified by qPCR. Again, DC-SIGN and WGA retained HCMV particles, suggesting the presence of high-mannose sugars on viral particles. It is interesting to note that O-glycans were readily recognized by MPA on virions most likely on glycoproteins other than gB. Apparently, no sialic acid (SA) residues could be detected on virions. These results demonstrated that CHOderived gB and HIV-1 gp120 are decorated with high-mannose sugars on N-glycans. We also showed that gB and whole HCMV particles share similar glycans contents except for O-glycans.
High-Mannose Sugars Decorating Glycoprotein B Enable Its Binding
to Dendritic Cell-Specific Intercellular Adhesion Molecule-3-Grabbing
Nonintegrin
Next, we examined the contribution of gB glycans to the interaction with DC-SIGN. Hence, various glycosidases were used to selectively remove sugars from gB. Although a moderate decrease of the gB molecular weight (MW) was observed after a mannosidase treatment, the PNGase F digestion induced a clear shift in the apparent gB MW, confirming that N-glycans account for a substantial part of the molecule ( Figure 3A) . Neuraminidase (NA)-treated gB also exhibited an altered electrophoretic mobility compared with nontreated gB, likely indicating an unexpected presence of SA based on results shown in Figure 3 .
We then measured the affinity of DC-SIGN for untreated or deglycosylated gB by surface plasmon resonance spectroscopy. Apparent dissociation constants (K d app ) were calculated from the sensorgrams presented in Figure 3B . The K d app values were extrapolated using a kinetic model ( Figure 3B ). Untreated gB had a K d app of 14 pM ( Figure 3C ). Sialic acid removal did not seem to alter the binding to immobilized DC-SIGN extracellular domain (K d app = 25 pM), indicating that SA are not important, in line with our results in Figure 2D . In contrast, the mannosidase activity led to a marked K dapp increase (149 pM), suggesting a function for terminal mannose residues. The PNGase F-treated gB had an even higher K d app (230 pM) in that setting, confirming that N-glycans are crucial ( Figure 3C ). The relatively limited K d app increase upon removal of N-glycans was associated to an incomplete PNGase F digestion in regular conditions [37] . By adding sodium dodecyl sulfate to the PNGase F or using the trifluoromethanesulfonic acid to chemically deglycosylate gB, we confirmed our hypothesis (Supplementary Figure 2) . HIV-1 gp120 binding (MFI) Dendritic cell-SIGN is a high-mannose sugar specific lectin. We looked for the presence of high-mannose sugars on gB. Electrophoretic mobilities of Endo Hf-treated or untreated gB were compared ( Figure 3D ). Endo Hf removed high mannoses on gB in denaturing (D) and in non-denaturing (ND) conditions but with an extended incubation time (O/N) compared with untreated gB. We showed that Endo Hf-treated gB significantly lost its ability to interact with WT DC-SIGN-expressing HEK293T cells compared with untreated gB ( Figure 3E) . Altogether, these data show that high-mannose on N-glycans but not SA are crucial for the gB/DC-SIGN interaction.
Antibodies Against Antigenic Domains 4 and 5 Impair the Glycoprotein B/Dendritic Cell-Specific Intercellular Adhesion Molecule-3-Grabbing

Interaction
To better define the DC-SIGN/gB interaction, we first used mAbs against AD-1 (clones ITC33, ITC39, ITC48, ITC52, and ITC63B) and AD-2 (clone ITC88) for blockade experiments [27] . None of these mAbs blocked the binding except the polyclonal, which demonstrated that AD-1 or -2 were not involved ( Figure 4A ). Two mAbs, clones SM5-1 and 1G2 recognizing AD-4 and AD-5, respectively [8] , were further tested. Results showed a partial but significant blocking activity of both antibodies up to 48% loss of binding on DC-SIGN + U937 or MDDC, suggesting that AD-4 and AD-5 could be responsible for the interaction with DC-SIGN ( Figure 4B ). It is noticeable that DC-SIGN appeared as the only cellular receptor for gB because the pAb-mediated blockade totally abrogated binding on DC-SIGN+ U937 compared with parental cells ( Figure 4B , left graph). Those antibodies were also used to block HCMV trans-infection by DC-SIGN + cells, which relies on the transfer of DC-SIGN + cells-immobilized HCMV virions, ie, either stuck on the plasma membrane or endocytosed, to HCMV permissive cells. We were surprisinged to find that although 1G2 consistently blocked half of the trans-infection by DC-SIGN + U937 cells, the SM5-1 clone totally abrogated it ( Figure 4C ). We hypothesized that this was due to the SM5-1 ability to block the pre-fusion to intermediate or postfusion transition, thus impairing fusion and eventually the infection of MCR-5 cells [38] . Similar results were obtained with 4 low-passage HCMV strains, ie, TB40/E-GFP, VHL/E, Toledo, and a clinical isolate from our center (TRI) on MDDC ( Figure 4D ). Therefore, we concluded that AD-5 and AD-4 were both responsible for the interaction with DC-SIGN.
Mutating the Asparagine At Position 208 on Glycoprotein B Impairs Its Interaction With Dendritic Cell-Specific Intercellular Adhesion
Molecule-3 and Subsequent Transinfection
Antigenic domain-4 and AD-5 are heavily N-glycosylated on HCMV gB [39] . To identify the high-mannose sugar-containing N-glycans recognized by DC-SIGN on gB, all putative N-glycosylation sites were mutated and expressed in HEK293T cells (see Methods, Supplementary Figure 3 , and Supplementary Table 1 ). Wild-type or mutated gB in non-denatured cell lysates were immobilized on a nitrocellulose membrane. The capacity of DC-SIGN-Fc to bind to gB in all conditions was calculated on a normalized gB expression. Values ranged from 0.24 for the negative control (ie, empty pRC-CMV vector) to 1.15 for WT gB. The N208A mutation located in AD-5 led to a significant DC-SIGN-Fc binding decrease, suggesting that N-glycans on this residue are important, although other mutants found in AD-4 and AD-5 (from N281A to N409A) behaved similarly ( Figure 5A) .
We sought to determine whether such a mutation could alter the binding of a whole HCMV particle. To that end, we took advantage of the "en-passant" mutagenesis strategy developed by Tischer et al [40] to modify the UL55 sequence in the genome of the TB40 HCMV strain (BAC4) to generate gB-mutated virions. Virions bearing N208A, N417A, N447A, N452A, and N585A mutations were reconstituted with similar yields ( Figure 5B ) reaching a plateau at day 16 postinfection (approximately 1 × 10 7 genome copies/mL), indicating that mutations did not notably alter growth kinetics during reconstitution ( Figure 5C ). Then, we demonstrated that the N208A mutation exhibited a significantly altered trans-infection ability ( Figure 5D ). We showed that all mutated and WT virions were infecting MRC-5 cells similarly at the same time point, ie, day 2 postinfection (Figure 5E ). We concluded from these results that gB interacts with DC-SIGN mainly through high-mannose containing N-glycans on the asparagine at position 208.
Antibody-Mediated Targeting of Dendritic Cell-Specific Intercellular Adhesion Molecule-3 Blocks Glycoprotein B Binding and Neutralizes
Trans-Infection
Next, we looked at the blockade of the DC-SIGN/gB interaction with specific Abs to DC-SIGN. First, we characterized the specificity of 15 anti-DC-SIGN mAbs by flow cytometry on WT DC-SIGN, Δneck-or ΔCRD-expressing cell lines. We identified 9 anti-CRD mAbs (7 to 15). Monoclonal Ab 1 was listed as an anti-CRD or -ECPR antibody (Supplementary Table 2 ). All mAbs were tested in parallel with commercial Abs, 1 antineck (H200), and 3 additional anti-CRD antibodies (1B10, AZN-D1, and MR-1), to block gB binding to DC-SIGN. Almost all anti-CRD mAbs including commercial ones were moderate to high inhibitors of this interaction. For mAbs 12 to 15, a total abrogation of gB binding was even observed (Figure 6A ). Similar results were obtained with MDDC, confirming that targeting the DC-SIGN CRD almost totally abrogates gB binding ( Figure 6B ). To clarify whether other known HCMV receptors could participate to this interaction, we analyzed expression of PDGFRα [41] , β 1 chain integrin [42] , and α V β 3 integrin [42] on U937 cells and MDDC. Whereas MDDC displayed low to moderate expression levels for all tested receptors, U937 expressed the β 1 chain integrin and PDGFRα. However, none of these HCMV receptors could be linked to our observations. Therefore, we concluded that DC-SIGN is the major, if not the only, attachment receptor for gB on MDDC and DC-SIGN + U937 cells. Finally, we tested some anti-DC-SIGN CRD mAbs in trans-infection blockade experiments. All were shown to drastically neutralize the TB40/E-GFP trans-infection by MDDC or DC-SIGN + U937 cells (62% to 75% reduction; Figure 7A and Supplementary Figure 5) . Similar results were obtained with VHL/E and Toledo and with an in-house-generated clinical isolate (TRI) (inhibitions ranging from 67% to 83%, 70% to 86%, and 79% to 87.5%, respectively; Figures 7B-D) . Taken together, these results establish that blocking the DC-SIGN CRD prevents gB binding and almost completely neutralizes HCMV trans-infection.
DISCUSSION
In this study, we characterized the DC-SIGN/HCMV gB interaction. We identified DC-SIGN AA residues involved through an extensive mutagenesis study. We also demonstrated the importance of high mannose N-glycans decorating the asparagine residue in position 208 on gB, although others might be involved too. Finally, antibody-mediated blockades allowed us to identify DC-SIGN as a major attachment molecule for HCMV on MDDC. Mutating DC-SIGN has confirmed a crucial role for the 2 Ca 2+ binding sites and the glycan binding pocket in the recognition of gB, arguing in favor of a common interaction mode for all DC-SIGN viral ligands described to date, ie, HIV-1 gp120 or HSV-1/HHV-8 gB [36, 43] . Su et al [33] showed that turning the V351 into an alanine abrogated the HIV-1 gp120 binding. Our observation is consistent with this and indicates that a glycine residue instead of a valine at position 351 is deleterious. In contrast, replacement of this valine by a threonine, both having similar electron densities, has no effect, indicating that the fold matters at this position. In this study, we showed that the DC-SIGN neck is dispensable for gB binding, although 2 anti-neck mAbs, ie, 4 and 6 (Supplementary Figure 5) , were shown to block HCMV trans-infection. We hypothesized that the neck-dependent DC-SIGN microclustering at the plasma membrane was dispensable for soluble gB fixation to DC-SIGN but mandatory for the HCMV attachment to its target cells by permitting multiple ligand/receptor interactions. We identified gB AD-5 and, more precisely, high mannose-containing N-glycans harbored by the asparagine, at least in position 208, as responsible for the recognition of DC-SIGN. Based on structural homologies and functional studies, Sharma et al [44] proposed that HCMV gB could be classified as a class III fusion protein. Class III fusion proteins exist as pre-and postfusion states and possibly as conformational intermediates [45] . By analogy to a VSV-G pre-fusion crystal structure, a first model of a putative pre-fusion HCMV gB conformation was proposed by Spindler et al [38] . More recently, a study based on electron cryotomography showed for the first time that membrane-associated HSV-1 gB should exist because at least 2 distinct conformations reported as pre-and postfusion conformations [46] . Due to a high degree of similarity between HSV-1 and HCMV gB sequences, it is tempting to speculate that the latter exists at least as pre-and postfusion states. It is interesting to note that in the pre-fusion model reported by Zeev-Ben-Mordehai et al [46] , AD-5 and AD-4 protrudes out of HCMV gB, potentially providing an accessible platform for DC-SIGN. In contrast, in line with a former work [47] , Fontana et al [48] propose that the pre-fusion model described by Zeev-Ben-Mordehai et al [46] could be an intermediate between the pre-and postfusion states. They also suggested that the fusion loop points toward the viral membrane instead of pointing toward the cellular target membrane in the pre-fusion model of HSV-1 gB. In that setting, we can assume that DC-SIGN might be long enough to contact AD-4/AD-5 regardless of their respective locations into the pre-fusion model. Further investigations are needed to establish whether DC-SIGN can interact with HCMV gB pre-fusion conformation only or if it can adapt itself to distinct conformational states of HCMV gB.
CONCLUSIONS
In conclusion, we characterized the DC-SIGN/gB interaction in the present study. This work provides the molecular bases to understand how some anti-CRD mAbs can efficiently block the gB/DC-SIGN interaction. It should also help to rationally design other blockers of this interaction with antiviral properties. We propose that the DC-SIGN/gB interaction represents the most important HCMV attachment receptor on MDDC. Whether this holds true with other human tissue-resident DC or macrophages expressing DC-SIGN remains to be established. The relevance of our results now has to be challenged in appropriate models. To date, few single-nucleotide polymorphisms described in the 5' untranslated region of the CD209 gene are associated with variable expression of DC-SIGN on MDDC [49] . Unexpectedly, the GG genotype (rs735240), which leads to a decreased DC-SIGN expression on MDDC, was shown to correlate (1) with increased CMV reactivation or disease in allogeneic stem cell transplantation patients [49] and (2) with decreased CMV infection-free survival in kidney transplant patients [50] . Further investigations are now required to reconcile our in vitro results with clinical observations.
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